Exabis Library
Welcome to the e-CCO Library!
OP32 Mincle signalling promotes intestinal mucosal inflammation through induction of macrophage pyroptosis and neutrophil chemotaxis in Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
OP32: A novel mechanism of colonic epithelial-T-cell cross-talk is dysregulated in IBD
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
OP32: Pyroptosis Inhibition Prevents the Cytotoxicity Induced by IL-17 Without Impairing Its Beneficial Effects
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
OP32: Stool microbiome communities predict remission in treatment-naïve Pediatric Crohn’s Disease patients
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
OP32: The gut virome-colonizing Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
OP33 Multi-omics analysis reveals specific bio-geographical and functional characteristics in inflammatory bowel disease intestinal mucosa
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
OP33: BUB1: a new player in the development of Crohn’s disease (CD)-associated fibrosis
2019
ECCO '19 Copenhagen
Thursday, 28 February 2019, 8:13 AM
1
OP33: Effect of upadacitinib (UPA) treatment on extraintestinal manifestations (EIMs) in patients with moderate-to-severe Ulcerative Colitis (UC): Results from the UPA Phase 3 programme
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
OP33: Oral ritlecitinib and brepocitinib in patients with Moderate to Severe Active Ulcerative Colitis: Data from the VIBRATO umbrella study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
OP33: Results of a randomised controlled trial to evaluate Interleukin 1 blockade with anakinra in patients with acute severe ulcerative colitis (IASO)
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
OP34 Whole blood profiling of T-cell-derived miRNA allows the development of prognostic models in inflammatory bowel disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
OP34: AJM300, an Oral Antagonist of α4-Integrin, as induction therapy for patients with Moderately Active Ulcerative Colitis: A Phase 3, randomized, double-blind, placebo-controlled induction study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
OP34: Efficacy and safety of advanced induction and maintenance therapies in patients with moderately to severely active Ulcerative Colitis: An indirect treatment comparison using Bayesian network meta-analysis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
OP34: Enteral Nutrition Compared with Steroids in Children with Crohn's Disease – In Israel: a nationwide study from the epi-IIRN
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
OP34: VARSITY: A double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis
2019
ECCO '19 Copenhagen
Thursday, 28 February 2019, 8:13 AM
OP35 Treatment outcomes of inflammatory bowel disease in the biological era—a nationwide retrospective cohort study in three Nordic countries: Results from the TRINordic study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
OP35: Effect of maintenance ustekinumab on corticosteroid-free endoscopic and clinical outcomes in patients with Crohn's Disease - Week 48 analysis of the STARDUST trial
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
OP35: Efficacy and safety outcomes up to ~4 years of treatment with filgotinib 200 mg among patients with Ulcerative Colitis: Results from the SELECTIONLTE study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
OP35: Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
OP35: Natural history of anal ulcerations in pediatric-onset Crohn's Disease: A population-based study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM